The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.
Manish A. Shah
Consultant or Advisory Role - Genentech
Eric Van Cutsem
Research Funding - Roche
Yoon-Koo Kang
Consultant or Advisory Role - Roche
Honoraria - Roche
Shaker R. Dakhil
No relevant relationships to disclose
Taroh Satoh
Consultant or Advisory Role - Chugai Pharma
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Keisho Chin
No relevant relationships to disclose
Yung-Jue Bang
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Lilian Bu
Employment or Leadership Position - Roche
Grozdana Bilic
Employment or Leadership Position - Roche
Atsushi Ohtsu
Honoraria - Chugai Pharma; Novartis; Roche; Taiho Pharmaceutical